OBJECTIVES: Previous studies have compared the outcomes of mitral annuloplasty with those of mitral valve replacement in patients with functional mitral regurgitation. However, data comparing the results of tricuspid annuloplasty (TAP) with those of tricuspid valve replacement (TVR) in patients with functional tricuspid regurgitation (FTR) have been scarce. We evaluated whether TAP was an optimal option for severe FTR.
INTRODUCTION
Functional tricuspid regurgitation (FTR) deferred to tricuspid regurgitation (TR) occurrs without organic leaflet pathology. It results from (i) tricuspid annular dilatation, primarily in the anteroposterior direction, and (ii) increase in the leaflet-tethering height, and reduction in the coaptation surface area between leaflets, due to right ventricular dilatation and changes in right ventricular geometry [1] . Most patients with FTR undergo tricuspid annuloplasty (TAP), using annular plication sutures or prosthetic rings [2] [3] [4] [5] . However, there has been concern that the long-term results of TAP, even after using prosthetic rings, might be suboptimal in terms of freedom from recurrent TR [1, 2] . Failure of the TAP and resultant tricuspid reoperation can be a high-risk procedure [6, 7] . Although recent studies have compared the outcomes of mitral annuloplasty with those of mitral valve replacement in patients with functional mitral regurgitation [8] [9] [10] , data comparing the results of TAP with those of tricuspid valve replacement (TVR) in FTR have been scarce. At our institution, TVR has been frequently performed in patients with severe FTR with and without combined cardiac disease to avoid future reoperations.
We evaluated whether the long-term clinical outcomes of TVR were beneficial compared with those of TAP in patients with severe FTR.
MATERIALS AND METHODS

Patient characteristics
The study protocol was reviewed by the Institutional Review Board and was approved as a minimal risk retrospective study (Approval Number: H-1306-089-498), which did not require individual consent based on the institutional guidelines for waiving consent.
From January 1996 to December 2012, 175 patients (57 ± 11 years old, male : female = 51 : 124) underwent surgical correction for severe FTR. Patients with histories of previous TAP and those with organic tricuspid leaflet pathology were excluded. One hundred and eight patients underwent TAP (the TAP group) and 67 patients underwent TVR (the TVR group). In the TAP group, 77 patients underwent suture annuloplasty, and 31 underwent annuloplasty using prosthetic rings. In the TVR group, 30 patients underwent mechanical TVR, and 37 underwent bioprosthetic TVR. There were differences in the preoperative characteristics between the two groups, such as smoking history, previous cardiac surgery and New York Heart Association functional class (Table 1) .
Surgical procedures and operative data
The surgical techniques for TVR and TAP have been previously described [11] [12] [13] . All operations were performed under routine aorto-bicaval cannulation, moderate hypothermia and cold cardioplegic arrest via a median sternotomy. Until 2002, TAP was preferred for the majority of patients (TAP, n = 38; TVR, n = 5). Subsequently, TVR has been performed more frequently at the discretion of the attending surgeons.
The concomitant cardiac procedures included mitral valve operations (n = 98), arrhythmia surgeries (n = 62) and aortic valve procedures (n = 40). More patients in the TAP group underwent concomitant surgeries, such as mitral valve operations (P < 0.01) and arrhythmia surgeries (P < 0.01), than in the TVR group. The mean cardiopulmonary bypass and aortic cross-clamp times were 199 ± 76 and 122 ± 55 min, respectively ( Table 1) .
Evaluation of early and long-term clinical outcomes
Patients underwent regular postoperative follow-ups through the outpatient clinic at 3-or 4-month intervals, and they were contacted by telephone for confirmation of their conditions if the last clinic visit was not conducted at the scheduled time. The anticoagulant dose was adjusted to obtain a target international normalized ratio (INR) of 2.5 for the patients with left-sided heart valve and/or atrial fibrillation and an INR of 3.0 for the patients with mechanical tricuspid valves. A specialized anticoagulation service team comprised of experienced pharmacists regularly followed up all patients. The clinical follow-up was closed in June 2013. The follow-up was completed in 96% of patients (168 of 175), with a follow-up duration of 83 months (range 3-212 months). The operative mortality was defined as death occurring within 30 days or during the same hospitalization as the surgery. Cardiac death was defined as any death related to cardiac events, including sudden death during follow-up. The valve-related complications were recorded according to the previous guidelines [14] . The tricuspid valve-related events (TVREs) included the following events: (i) cardiac death; (ii) structural valve deterioration of the replaced valve or recurrent TR after TAP; (iii) tricuspid valve reoperations; (iv) congestive heart failure requiring readmission; (v) a composite of thromboembolism and bleeding that caused death, hospitalization or permanent injury, or that necessitated a transfusion; (vi) tricuspid valve endocarditis and (vii) permanent pacemaker implantation within 1 month post surgery.
Echocardiographic evaluation
An initial postoperative echocardiographic evaluation was performed before patient discharge. Follow-up echocardiograms were performed at the discretion of the operating surgeon or the referring physician during the follow-up. At least one echocardiogram was performed in 94% (152 of 162) of the survivors. The last follow-up echocardiogram was performed 63 ± 47 months after the surgery. Tricuspid regurgitation was graded from 0 to 4+: 0 = none, 1+ = mild, 2+ = moderate, 3+ = moderately severe and 4+ = severe. Recurrent TR was defined as TR equal to or worse than Grade 3 post surgery.
Statistical analysis
The statistical analysis was performed using the SPSS software package (version 12.0; SPSS, Inc., Chicago, IL, USA). The data are expressed as the means ± standard deviations, medians with ranges or proportions. Comparisons between the two groups were performed with the χ 2 test or Fisher's exact test for the categorical variables and Mann-Whitney U-test for the continuous variables. A multivariable analysis for operative mortality was performed with a logistic regression analysis. The survival rates were estimated using the Kaplan-Meier method, and comparisons between two groups were performed with the log-rank test or the Cox regression model. The Cox proportional hazard model was adopted for the analyses of risk factors for time-related events. The group factor and other variables with a P-value <0.1 were entered into the multivariable analyses. A P-value of <0.05 was considered statistically significant.
To overcome the baseline differences between the two groups, a propensity score of undergoing TVR was calculated. Inverse probability of treatment weighting (IPTW)-adjusted analysis and 1 : 1 propensity score matching were performed. The underlying characteristics considered in the estimation of propensity score included the following: (i) age, (ii) sex, (iii) smoking, (iv) body mass index, (v) diabetes mellitus, (vi) hypertension, (vii) chronic obstructive pulmonary disease, (viii) history of stroke, (ix) chronic renal failure, (x) New York Heart Association functional class ≥3, (xi) coronary artery disease, (xii) atrial fibrillation, (xiii) left ventricular dysfunction (left ventricular ejection fraction <50%) and (xiv) previous cardiac surgery. The P-value of the HosmerLemeshow test and the c-statistic of the propensity score model, which reflected the calibration and discrimination powers of the propensity score model, were 0.83 and 0.89, respectively. In the IPTW adjustment, the weights for the patients receiving TVR were the inverse of the propensity score, and the weights for the patients receiving TAP were the inverse of 1 minus the propensity score. The propensity score-matching analysis extracted 37 patients from each group. For the comparison of the categorical and continuous variables between the matched groups, McNemar's test and Wilcoxon signed-rank test were performed.
RESULTS
Early results
The operative mortality rate was 7.4% (13 of 175) without intergroup differences [TAP versus TVR groups = 6% (6 of 108 patients) versus 10.4% (7 of 67 patients), P = 0.25]. The early postoperative morbidities included low cardiac output syndrome (n = 28, 16%), postoperative bleeding requiring reoperation (n = 9, 5%), acute renal failure (n = 9, 5%) and stroke (n = 4, 2%). There were no differences in the postoperative complications between the two groups ( Table 2 ). In the IPTW-adjusted multivariable analysis, the group factor was not associated with operative death [P = 0.85, odds ratio (OR), 95% confidence interval (CI) = 0.840, 0.145-4.849]. A longer cardiopulmonary bypass time was the only predictor of operative mortality after surgery (P < 0.01, OR = 1.013, 95% CI = 1.004-1.022).
Long-term survival
Among the 162 survivors, late death occurred in 35 patients, including 24 cardiac deaths. The overall survival rates at 5, 10 and 15 years were 83.3, 72.8 and 66.8%, respectively. The overall survival rates were higher in the TAP group than in the TVR group. However, the difference did not reach statistical significance (P = 0.18, Fig. 1 ). The freedom rates from cardiac death at 5, 10 and 15 years were 88.2, 80.5 and 80.5%, respectively. These rates were higher in the TAP group than in the TVR group (P = 0.01, Fig. 2 ). The IPTW-adjusted Cox proportional hazard model revealed that valve replacement was a significant risk factor for long-term cardiac death (Table 3 , Fig. 2 ).
Freedom from tricuspid valve-related events
In the TAP group, structural valve deterioration (TR ≥3+) occurred in 13 patients (3+ in 5 and 4+ in 8) during the follow-up. Seven patients underwent tricuspid valve reoperations, with (n = 4) or without (n = 3) other cardiac procedures. Among these, 1 patient who underwent redomitral and tricuspid valve surgery for fungal endocarditis of both valves died after the reoperation because of an unresolved fungal infection. Bleeding events occurred in 8 patients. Readmission was required because of congestive heart failure in 12 patients. Infective endocarditis occurred in 1 patient. 
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In the TVR group, structural valve deterioration and a paravalvular leak occurred in 1 patient each. Tricuspid valve thrombosis occurred in 1 patient, who was treated with anticoagulation medication. Bleeding events occurred in 6 patients. Readmission because of congestive heart failure was required in 10 patients. Infective endocarditis occurred in 1 patient. No patient underwent a tricuspid valve reoperation during the follow-up.
The 5-, 10-and 15-year TVRE-free rates were 80.9, 61.4 and 61.4%, respectively. The rates were similar between the two groups (P = 0.50).
Results of propensity score-matching analysis
After propensity score matching, there were no differences in demographic data and preoperative risk factors between the two groups. However, concomitant mitral and aortic valve procedures were performed more frequently in the TAP group than in the TVR group (Table 4) . Early mortality occurred in 8 patients (11%). The incidences of early mortality and postoperative complications were similar between the two propensity score-matched groups ( Table 5 ). The 10-year overall survival and freedom from cardiac death rates were 75.8 and 78.2%, respectively. The overall survival rates were similar between the two groups (P = 0.74). However, the freedom rates from cardiac death were higher in the TAP group (90.7, 86.8 and 86.8% at 5, 10 and 15 years, respectively) than in the TVR group (83.2, 67.9 and 67.9% at 5, 10 and 15 years, respectively), although the difference was not statistically significant (P = 0.13, Fig. 3 ).
In the TAP group, one or more TVREs occurred in 9 patients, including cardiac death (n = 4), structural valve deterioration (n = 3), tricuspid valve reoperation (n = 3), bleeding events (n = 5), readmission for congestive heart failure (n = 3) and infective endocarditis (n = 1). In the TVR group, TVREs occurred in 16 patients, including cardiac death (n = 9), paravalvular leak (n = 1), tricuspid valve thrombosis (n = 1), bleeding (n = 3) and congestive heart failure (n = 8). There was a trend towards higher 5-, 10-and 15-year TVRE-free rates in the TAP group (77.3, 73.2 and 62.8%, respectively) compared with the TVR group (72.4, 39.9 and 39.9%, respectively) (P = 0.07, Fig. 3 ).
DISCUSSION
This study demonstrated that TAP should be considered as the treatment of choice in patients with severe FTR because TVR has been associated with long-term cardiac death and TVREs, although the reoperation rate was higher after TAP than after TVR.
Most patients with FTR obtain satisfactory results with TAP. However, in patients with FTR of a moderate-to-severe degree, there has been concern that the results of TAP with or without a prosthetic ring might be less satisfactory, and the recurrence of TR has not been infrequent, even during the early period after surgery [2, 3] . A previous study demonstrated that 15% of 789 patients experienced recurrent TR ≥3 at 1 month after TAP, even in patients who underwent TAP using prosthetic rings [3] . The subsequent tricuspid reoperation because of TAP failure could result in high operative mortality [6, 7] .
Traditionally, mitral annuloplasty has been preferred for patients with functional mitral regurgitation [15] . However, there has been concern that mitral annuloplasty is unsatisfactory for patients with functional mitral regurgitation [8, 9] . A recent study demonstrated that, in a propensity score-adjusted multivariable analysis of 132 patients, mitral valve replacement was associated with higher in-hospital and late mortalities compared with mitral valve repair in patients with dilated and ischaemic cardiomyopathies [10] . In another study, however, the authors suggested performing mitral valve replacement because the mitral valve repair was associated with an increased risk of reoperation without any benefits compared with mitral valve replacement [9] .
The present study was inspired by a similar question. Is TAP sufficient to treat FTR, particularly FTR of a severe degree? Contrary to numerous studies of functional mitral regurgitation, however, only a few studies have compared the results of TAP with those of TVR [16, 17] . One of the most important limitations when comparing the results of TAP with those of TVR is that there might be baseline differences between the patients who underwent TVP and those who underwent TVR. To overcome this limitation, a previous study compared the results of TAP with those of TVR using propensity score-matching analysis [18] . The authors matched 68 patients in each group, and they demonstrated that there were no advantages favouring TAP over TVR in terms of the long-term clinical outcomes. In their study, however, they demonstrated only overall survival as a long-term clinical outcome. In the present study, to minimize selection bias, we only enrolled patients with FTR of a severe degree. However, there were still baseline differences between the two groups. To overcome these differences, we constructed a propensity score model that included 14 variables, and the baseline differences were adjusted using two methods: IPTW-adjusted multivariable analysis [17] and propensity score matching. After these adjustments, TVR was associated with a high rate of long-term cardiac death. This finding aligned with the results of previous studies reporting higher longterm mortality after TVR compared with mortality after TAP [19, 20] . A theoretical disadvantage of TVR that has been suggested is progressive right ventricular dysfunction, which might occur after TVR because of a large, rigid prosthetic object being inserted into a deformable, low-pressure cavity [19, 20] .
In the TAP group, 8 patients experienced recurrent FTR of a severe degree, and 7 underwent tricuspid valve reoperations. However, there were no differences in the TVRE-free rates between the two groups for the entire patient group, and there was a trend towards higher TVRE-free rates in the TAP group than in the TVR group in the propensity score-matched patient population. The majority of patients in the TAP group in the present study underwent TAP without a prosthetic ring, which has been suggested to be a risk factor for recurrent TR after TAP [21] . Our current practice includes a modification of suture annuloplasty and 3D ring annuloplasty [12, 13] . It is expected that improved results with TAP might further decrease the risks of cardiac death and TVREs in the TAP group.
The present study had limitations that must be noted. Firstly, the present study was a retrospective, observational study that was conducted at a single institution. Although we enrolled only patients with severe FTR, and we performed IPTW-adjusted analysis and propensity score matching, selection bias and confounding variables might have affected the study results. Secondly, the indications for TAP and TVR were not precisely defined because of the retrospective nature of the present study. Thirdly, the followup duration was different between the two groups because we preferred performing TAP during the early period of the study. Fourthly, the technique of TAP changed over time with later use of annuloplasty rings. Finally, the number of patients enrolled in the present study might be too small to draw definite conclusions. A randomized, controlled trial with a large cohort might be necessary to reach more definitive conclusions.
